Three months of CGRP antibody therapy for migraine did not impair the brain's ability to regulate its own blood supply, though patients who responded to treatment showed slightly reduced blood flow velocity.
Autoregulation preserved3 months of CGRP antibody therapy did not impair cerebral autoregulation or reactivity — reassuring safety data for this peptide-targeting drug class
What the researchers found
Three months of CGRP monoclonal antibody therapy in migraine patients preserved cerebral autoregulation (CA) and cerebrovascular reactivity (CVR) in both the middle and posterior cerebral arteries (all p>0.38). Blood flow velocity and blood pressure were also unaffected overall. However, patients who responded clinically (>50% migraine reduction) showed a small but significant reduction in cerebral blood flow velocity in MCA (6.0 cm/s, p=0.007) and PCA (8.9 cm/s, p=0.04).
Why it matters
CGRP is a potent brain blood vessel dilator, raising concerns that blocking it could impair cerebral blood flow regulation and increase stroke risk. This study provides reassuring evidence that CGRP antibody therapy preserves the brain's critical safety mechanisms (autoregulation and reactivity), while the small blood flow change in responders could serve as a treatment response biomarker.
The numbers in context
n=23 · 3 months treatment · CA unchanged (MCA p=0.42, PCA p=0.72) · CVR unchanged (MCA p=0.38, PCA p=0.92) · responders: MCA-CBFv -6.0 cm/s (p=0.007), PCA-CBFv -8.9 cm/s (p=0.04)
How the study worked
Prospective study of 23 patients with chronic or episodic migraine. Transcranial Doppler ultrasound measured cerebral blood flow velocity in MCA and PCA before and 3 months into CGRP monoclonal antibody therapy. Cerebrovascular reactivity (CVR) and cerebral autoregulation (CA; Mx-index) were calculated. Subgroup analysis compared clinical responders (>50% migraine frequency reduction) to non-responders.
Who was studied
23 adults with chronic or episodic migraine, assessed before and during CGRP monoclonal antibody therapy
What this study cannot tell us
Small sample size (n=23). No control group — observed changes could reflect disease natural history. The responder subgroup analysis had even fewer participants, limiting reliability. Only one time point (3 months) assessed. Cannot determine if blood flow velocity changes are clinically meaningful or represent a safety concern. The study assessed interictal (between-migraine) hemodynamics only.
How to read the evidence
This is a small prospective observational study (n=23) without a control group. While it provides valuable preliminary safety data using validated cerebrovascular monitoring techniques, the small size and lack of controls limit definitive conclusions. Larger, controlled studies are needed.
When this study was published
Published in 2024, this study addresses an important and timely safety question as CGRP-targeting therapies rapidly expand in clinical use. It provides some of the first direct measurements of cerebrovascular physiology under CGRP blockade.
The bigger picture
As CGRP-targeting therapies become first-line migraine prevention for millions of patients, understanding their cerebrovascular safety is critical. CGRP's role in brain blood vessel dilation had raised theoretical stroke risk concerns. This study, while small, adds to growing evidence that therapeutic CGRP blockade doesn't compromise cerebrovascular safety mechanisms — an important finding for the long-term adoption of this peptide-targeting drug class.
Questions still open
- Does the small blood flow velocity reduction in responders reflect a beneficial normalization of migraine-related vasodilation, or a potential concern?
- Would longer treatment durations (1+ years) show progressive changes in cerebral hemodynamics?
- Could transcranial Doppler blood flow measurements predict which migraine patients will respond to CGRP antibody therapy?
Common questions
Why were scientists worried about CGRP drugs affecting brain blood flow?
What does it mean that treatment responders had reduced blood flow velocity?
Read the original research
Effect of CGRP inhibitors on interictal cerebral hemodynamics in individuals with migraine.
Frontiers in neurology, 15, 1399792
Citation
Carter, Sarah C; Cucchiara, Brett; Reehal, Navpreet; Hamilton, Katherine; Kaiser, Eric A; Favilla, Christopher G. (2024). Effect of CGRP inhibitors on interictal cerebral hemodynamics in individuals with migraine.. Frontiers in neurology, 15, 1399792. https://doi.org/10.3389/fneur.2024.1399792